Last $13.80 USD
Change Today +0.07 / 0.51%
Volume 3.6K
As of 11:42 AM 07/28/14 All times are local (Market data is delayed by at least 15 minutes).

Financial Statements for astellas pharma inc-unsp adr (ALPMY)

Year over year, Astellas Pharma, Inc. has been able to grow revenues from ¥1.0T JPY to ¥1.1T JPY. Most impressively, the company has been able to reduce the percentage of sales devoted to cost of goods sold from 32.23% to 29.00%. This was a driver that led to a bottom line growth from ¥82.9B JPY to ¥90.9B JPY.
View Income Statement In U.S. Dollar
Currency in
Millions of Japanese Yens
As of:Mar 31
2011
Restated
JPY
Mar 31
2012
Restated
JPY
Mar 31
2013
Restated
JPY
Mar 31
2014
JPY
4 Year
Trend
Revenues953,948.0969,387.01,005,612.01,139,909.0
TOTAL REVENUES953,948.0969,387.01,005,612.01,139,909.0
Cost of Goods Sold295,973.0318,633.0324,127.0330,628.0
GROSS PROFIT657,975.0650,754.0681,485.0809,281.0
Selling General & Admin Expenses, Total321,468.0329,395.0345,663.0465,014.0
R&D Expenses217,326.0189,840.0181,955.0191,460.0
Depreciation & Amortization, Total------36,000.0
OTHER OPERATING EXPENSES, TOTAL538,794.0519,235.0527,618.0692,474.0
OPERATING INCOME119,181.0131,519.0153,867.0116,807.0
Interest and Investment Income2,338.02,365.01,806.01,590.0
NET INTEREST EXPENSE2,338.02,365.01,806.01,590.0
Income (Loss) on Equity Investments-89.0194.033.0--
Currency Exchange Gains (Loss)-6,556.01,005.01,464.0--
Other Non-Operating Income (Expenses)-300.08,271.0-2,402.0-460.0
EBT, EXCLUDING UNUSUAL ITEMS114,574.0143,354.0154,768.0117,937.0
Merger & Restructuring Charges-4,723.0-645.0----
Gain (Loss) on Sale of Investments1,280.02,716.05,428.03,850.0
Gain (Loss) on Sale of Assets-1,277.0-5,924.0-733.0188.0
Other Unusual Items, Total-5,811.0-12,427.0-34,790.0-1.0
Other Unusual Items-3,029.0-3,193.0----
EBT, INCLUDING UNUSUAL ITEMS104,043.0127,074.0124,673.0121,974.0
Income Tax Expense35,832.048,844.041,822.031,100.0
Earnings from Continuing Operations68,211.078,230.082,851.090,874.0
Extraordinary Item & Accounting Change-560.0------
NET INCOME67,651.078,230.082,851.090,874.0
NET INCOME TO COMMON INCLUDING EXTRA ITEMS67,651.078,230.082,851.090,874.0
NET INCOME TO COMMON EXCLUDING EXTRA ITEMS68,211.078,230.082,851.090,874.0
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ALPMY:US $13.80 USD +0.07

ALPMY Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $118.06 USD -0.31
CSL Ltd A$66.76 AUD -0.04
Mylan Inc/PA $50.52 USD -1.23
Takeda Pharmaceutical Co Ltd ¥4,710 JPY -3.50
Valeant Pharmaceuticals International Inc C$133.17 CAD -0.41
View Industry Companies
 

Industry Analysis

ALPMY

Industry Average

Valuation ALPMY Industry Range
Price/Earnings 7.1x
Price/Sales -- Not Meaningful
Price/Book 2.5x
Price/Cash Flow 25.5x
TEV/Sales 2.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTELLAS PHARMA INC-UNSP ADR, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.